China's first new crown mRNA vaccine has been approved for clinical trials.

Medicine Network June 28 - China News Agency reporters learned on the 25th, by the Chinese People's Liberation Army Military Academy of Military Medicine and local enterprises jointly research and develop the formation of a new coronavirus mRNA candidate vaccine (ARCoV) has been officially approved by the State Drug Administration clinical trial on June 19This is the first new crown mRNA vaccine approved for clinical trials in China.Since the outbreak of xinguan pneumonia, the Institute of Military Medicine of the Academy of Military Sciences has deployed emergency scientific research and promoted the development of new crown vaccines along several technical routesThe domestic new crown mRNA vaccine is another high-tech vaccine that has been successfully approved for clinical trials after recombining the new crown vaccine (adenovirus vector).Studies have shown that the new mRNA vaccine not only induces high levels of neutralizing antibodies in mice and crab-eating monkeys, but also induces a protective T-cell immune responseExperiments on crab-eating monkeys show that vaccine-immunized animals can withstand high-dropnew coronavirus attacks, effectively preventing virus replication and lung pathology progress, and show good protective effect.MRNA vaccine is a new form of vaccine in recent years, the basic principle is through a specific delivery system to express antigen targetmRNA into the body, in the body to express protein and stimulate the body to produce a specific immunological response, so that the body to obtain immune protectionMRNA vaccine research and development there is a high technical threshold, currently only the United States and Germany developed a few mRNA vaccine varieties into clinical research stage, China has never approved the mRNA vaccine into clinical.Qin Chengfeng, project leader and researcher of the Institute of Military Medicine of the Military Academy of Sciences, said that the domestic new crown mRNA vaccine has three advantages: First, the vaccine antigen target selection is more accurate, the induction of neutralizing antibody specificity is high, the vaccine safety is better;.It is reported that the new crown mRNA vaccine has been completed in accordance with the requirements of clinical trials, will be in Shulan (Hangzhou)Hospitalofficially launched Phase I clinical trials (Complete) .